From hPSCs to Immune Cells: Mechanisms of Selection in Human Pluripotent Stem Cell Cultures
Dr. Ivana Barbaric discusses how genetic mutations in hPSCs cultured in vitro confer selective advantages that can affect cell behavior and confound experimental results through the elimination of wild-type cells. Dr. Barbaric is a group leader at the Center for Stem Cell Biology, University of Sheffield, UK.
Dr. Ivana Barbaric discusses how genetic mutations in hPSCs cultured in vitro confer selective advantages that can affect cell behavior and confound experimental results through the elimination of wild-type cells. Dr. Barbaric is a group leader at the Center for Stem Cell Biology, University of Sheffield, UK.
This presentation and the following Q&A were moderated by Dr. Glyn Stacey from EuroStemCell and Dr. Adam Hirst from STEMCELL Technologies. It was part of the workshop “From hPSCs to Immune Cells”, hosted together with the London Stem Cell Network. During the event, scientists and experts presented on advancements in hPSC culture, the generation of immune cells, and the demands of cell therapy research. Explore the full series here >
This presentation and the following Q&A were moderated by Dr. Glyn Stacey from EuroStemCell and Dr. Adam Hirst from STEMCELL Technologies. It was part of the workshop “From hPSCs to Immune Cells”, hosted together with the London Stem Cell Network. During the event, scientists and experts presented on advancements in hPSC culture, the generation of immune cells, and the demands of cell therapy research. Explore the full series here >
Publish Date:
February 09, 2022
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
Related Multimedia
-
From hPSCs to Immune Cells: Immune Cell Generation from Human Pluripotent Stem Cells in Feeder- and Serum-Free Cultures
Publish Date: February 10, 2022 -
From hPSC to Immune Cells: Reagents for hPSC-Derived Cell and Gene Therapies
Publish Date: February 09, 2022 -
From hPSCs to Immune Cells: Generating Dendritic Cells by Direct Cell Reprogramming
Publish Date: February 10, 2022
Explore Our Products
-
cGMP, enzyme-free human pluripotent stem cell selection and passaging reagent -
qPCR analysis kit for detecting the majority of karyotypic abnormalities reported in human ES and iPS cells -
ReproTeSR™ Medium for Reprogramming (2-Component)
Reprogramming medium for human iPS cell induction
